相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Increased mTOR activation in idiopathic multicentric Castleman disease
Daniel J. Arenas et al.
BLOOD (2020)
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
Peter C. Taylor
RHEUMATOLOGY (2019)
Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry
Fan Zhang et al.
NATURE IMMUNOLOGY (2019)
Comprehensive Integration of Single-Cell Data
Tim Stuart et al.
CELL (2019)
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease
David C. Fajgenbaum et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis
Sachiko Hirose et al.
INTERNATIONAL IMMUNOLOGY (2019)
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Andrew Butler et al.
NATURE BIOTECHNOLOGY (2018)
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Przemyslaw J. Kotyla
BIOMED RESEARCH INTERNATIONAL (2018)
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee et al.
BLOOD (2018)
Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome
Noriko Iwaki et al.
SCIENTIFIC REPORTS (2017)
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum et al.
BLOOD (2017)
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease
Noriko Iwaki et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version
Yasufumi Masaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Human CD56bright NK Cells: An Update
Tatiana Michel et al.
JOURNAL OF IMMUNOLOGY (2016)
Plasma cells as an innovative target in autoimmune disease with renal manifestations
Falk Hiepe et al.
NATURE REVIEWS NEPHROLOGY (2016)
Idiopathic multicentric Castleman's disease: a systematic literature review
Amy Y. Liu et al.
LANCET HAEMATOLOGY (2016)
Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes
Mark Livingstone et al.
PLOS ONE (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Use of a claims database to characterize and estimate the incidence rate for Castleman disease
Nikhil Munshi et al.
LEUKEMIA & LYMPHOMA (2015)
Type I Interferon in the Pathogenesis of Lupus
Mary K. Crow
JOURNAL OF IMMUNOLOGY (2014)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Frits van Rhee et al.
LANCET ONCOLOGY (2014)
Regulation of type I interferon responses
Lionel B. Ivashkiv et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases
Massimo Gadina
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2013)
Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012)
Hiroshi Kawabata et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2013)
The clinical spectrum of Castleman's disease
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection
Michael A. Paley et al.
SCIENCE (2012)
Monocyte recruitment during infection and inflammation
Chao Shi et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Association of IRF5 polymorphisms with activation of the interferon α pathway
Ornella J. Rullo et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Genetic susceptibility to systemic lupus erythematosus in the genomic era
Yun Deng et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Type I Interferon Modulates Monocyte Recruitment and Maturation in Chronic Inflammation
Pui Y. Lee et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients
Timothy B. Niewold et al.
ARTHRITIS AND RHEUMATISM (2008)
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
N Nishimoto et al.
BLOOD (2005)
Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination
EJ Wherry et al.
JOURNAL OF VIROLOGY (2005)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Type I interferons produced by dendritic cells promote their phenotypic and functional activation
M Montoya et al.
BLOOD (2002)
Autoimmune lymphoproliferative syndrome - A human disorder of abnormal lymphocyte survival
JJH Bleesing et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2000)
分享论文
